Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs LMWH for VTE Prophylaxis After Bariatric Surgery
NCT06913595Phase 1Active, not recruiting
- Sponsor
- Cairo University
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Cairo University. Primary endpoint: Venous Thromboembolism at 1 year. Started Mar 2024; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06913595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913595.